ClinicalTrials.gg
Not yet recruitingNCT061927322EATUpdated Jan 5, 2024

Environmentally Sustainable Nutrition for Older Adults (55+) With Obesity

An interventional study of A more plant-based diet during weight loss in Obesity and Aging, sponsored by Amsterdam University of Applied Sciences. Not yet recruiting. Open to participants aged 55 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-05.

Sponsored by Amsterdam University of Applied Sciences · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2024, 2 years 6 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
55 Years and older
Sex
All
01

Study summary

The objective of the pilot study (feasibility study) is to assess the acceptability and feasibility of the developed 2EAT dietary treatment in obese older adults (55+).

For ecological reasons, the goal of the dietary treatment plan is to achieve an intake of 60% plant-based proteins in older adults (55+) in a healthy and nutritionally adequate way during a period of weight loss. The investigators developed the new dietary treatment plan for 6 months (RCT). To further optimize the new treatment plan the 2EAT study includes this feasibility study with a duration of 8 weeks.

In the feasibility study, the effect of a more plant-based hypocaloric diet on the protein intake of older adults (55+) with obesity is evaluated. To assess the feasibility of the treatment plan, 20 obese older adults will follow the newly developed dietary treatment for 8 weeks. The participants will be guided by experienced dieticians that are part of the study consortium, in their dietetic practice. All dieticians will be trained to execute the 2EAT dietary treatment plan.

The desired effect of the treatment is that participants change their protein intake and achieve an intake of 1.2 g/kg/d of which 60% is from plant-based sources. Additionally, the experience of both the older adults as well as the experience of the dieticians will be monitored during the 8 weeks of intervention. During 8 weeks there will be continuous monitoring of the implementation of the treatment plan by keeping logbooks (dieticians), and measurement of the food intake of the participants. When participants deviate from the diet, the dietician must make timely adjustments with available behavioral techniques. The primary outcome of the feasibility phase is the protein intake: source (plant-based vs. animal-based), amount (g/kg/day) and protein quality per meal (amino acid score). Secondary outcomes are the body weight and BMI of participants and qualitative information about the experience of participants and dieticians with the use of the new treatment plan. Dieticians are professionals in working with older clients with obesity during a weight loss program, and are competent to execute the treatment plan and additionally monitor and make adjustments to coach the participant towards the desired diet and goal. Findings and experiences from the 8-week feasibility study will be used to further improve the 2EAT dietary treatment. The optimized dietary plan will eventually be used in the RCT study.

02

Conditions studied

  • Obesity
  • Aging

Browse trials for

Keywords

  • Obesity
  • Older adults
  • Healthy ageing
  • Sustainability
  • Plant-based protein
  • Plant-based diet
  • Sustainable diets
  • Dietary counseling
03

In context

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

This study's planned enrollment of 20 is below the median of 67 across 9,043 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Amsterdam University of Applied Sciences is the lead sponsor of 6 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 55 or older
  • Are obese: have a of >30 kg/m2 or BMI >27 kg/m2 and waist circumference >88 cm (women) or >102 cm (men)
  • Living independently (not in a health facility)
  • The willingness that the general practitioner will be notified of study participation
  • Written
  • Willingness to comply with the protocol
  • Consent of the study physician

Exclusion criteria

Exclusion Criteria:

  • Inability to understand the Dutch language
  • Cognitive impairment ( \<15)
  • Use of total or partial parenteral nutrition (TPN)
  • Alcohol or drug abuse in the opinion of the investigator
  • Current enrolment in a fixed rehabilitation program or other intervention studies
  • Palliative treatment or a of ≤ 3 months
  • Following a vegan (100% plant-based) diet
  • Active medical treatment interfering with this intervention (e.g. cancer patients receiving systemic and immune therapy)
  • Physical disabled: unable to meet the general daily exercise guideline for adults
  • Planned a holiday during the intervention period and is unable to attend group- or individual sessions for > 1 week
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    More plant-based diet

    Participants receive the dietary counselling focused on a more plant-based diet during weight loss

    Behavioral: A more plant-based diet during weight loss

Interventions

  • BehavioralA more plant-based diet during weight loss

    Participants receive dietary counseling on a more plant-based diet during weight loss. They will be counseled by a dietician to increase their plant-based protein intake up to 60%, focusing on 1.2 grams of protein per kg body weight.

06

What researchers measure

Primary outcomes

  1. Assess the feasibility

    The objective of the feasibility study is to assess the feasibility of the developed 2EAT dietary treatment in obese older adults (55+). The feasibility focusses on the ratio plant-based and animal-based protein, where it is aimed to reach 60% plant-based proteins at endline (week 9). This will be investigated via 3-day dietary records (measured at baseline and endline).

    Time frame: Baseline (week 0) and endline (week 9)

  2. Assess the acceptability

    The objective of the feasibility study is to assess the acceptability of the developed 2EAT dietary treatment in obese older adults (55+). This will be investigated via focus groups. Focus groups will be organized for participants and dieticians separately at endline (week 9).

    Time frame: Endline (week 9)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2024; primary completion for May 2024, 3 months later.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 3 months is below that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2023
First posted
Jan 5, 2024
StartEst.
Feb 1, 2024
Primary completionEst.
May 1, 2024
CompletionEst.
May 1, 2024
Last update
Jan 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06192732
Lead sponsor
Amsterdam University of Applied Sciences
Responsible party
Sponsor
First posted
Jan 5, 2024
Start date
Feb 1, 2024 (estimated)
Primary completion
May 1, 2024 (estimated)
Completion
May 1, 2024 (estimated)
Last update
Jan 5, 2024

Study contacts

Susanne Wildemast
Contact
s.wildemast@hva.nl
+31623492734
Peter Weijs
principal investigator · Amsterdam University of Applied Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion